How many breakthrough outbreaks occur during suppressive therapy for HSV‑1?

Suppressive Therapy for HSV-1: Threshold for Initiation

Suppressive therapy for HSV-1 should be considered when patients experience 6 or more recurrent outbreaks per year, though the evidence for HSV-1 is weaker than for HSV-2. 1

Key Decision Points

Outbreak Frequency Threshold

• ≥6 recurrences per year: This is the traditional threshold where suppressive therapy reduces outbreak frequency by ≥75% 1
• HSV-1 specific consideration: The evidence base is predominantly from HSV-2 studies, and HSV-1 genital infections naturally recur less frequently than HSV-2 1

Important Caveats for HSV-1

The evidence quality differs significantly between HSV-1 and HSV-2:

• Most guideline recommendations are based on HSV-2 data [1-1]
• A 2022 systematic review specifically graded suppressive therapy for symptomatic genital HSV-1 as "B-low" evidence (recommended only among those with frequent recurrences), compared to "A-high" for HSV-2 2
• HSV-1 causes fewer recurrences overall, so fewer patients will meet the 6+ outbreak threshold 1

Practical Algorithm

For patients with genital HSV-1:

1. Document outbreak frequency over 6-12 months

   • If <6 outbreaks/year → episodic therapy preferred
   • If ≥6 outbreaks/year → offer suppressive therapy

2. Suppressive regimen options (same as HSV-2):

   • Acyclovir 400 mg twice daily, OR
   • Famciclovir 250 mg twice daily, OR
   • Valacyclovir 500-1000 mg daily 1

3. Reassess after 1 year of continuous therapy:

   • Discontinue to evaluate if outbreak frequency has naturally decreased 1
   • Many patients experience fewer recurrences over time

Special Populations

For HSV-1 herpes gladiatorum (wrestlers): Valacyclovir 500 mg daily effectively suppresses outbreaks in patients >2 years from primary infection; higher doses (1000 mg) may be needed for more recent infections 3

Early infection (<3 months): One study showed valacyclovir 1000 mg daily reduced HSV-1 recurrences from 3.4 to 1.7 outbreaks/year, though the benefit was less pronounced than for HSV-2 4

Common Pitfall

Do not assume HSV-1 and HSV-2 behave identically. While the same medications and thresholds are used, HSV-1 genital infections recur far less frequently, making suppressive therapy necessary in fewer patients. The quality of evidence supporting suppression for HSV-1 is substantially lower than for HSV-2 2.